CRISPR Sample Paper

Aisha Patel

August 2024

Abstract

Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal forms of primary brain cancer, with median survival under 15 months despite standard-of-care treatment. This study evaluates the efficacy of CRISPR-Cas9-mediated knockout of immune checkpoint genes as a complement to anti-PD-1 immunotherapy in syngeneic GL261 mouse models of GBM. We hypothesized that targeted disruption of PD-L1 expression on tumor cells would enhance T-cell infiltration and improve response to checkpoint blockade. Across three cohorts (n=24 mice per arm), the combined CRISPR + anti-PD-1 group showed a statistically significant 47% increase in median survival ($p < 0.01$) compared to anti-PD-1 alone, and a 2.3-fold increase in CD8+ tumor-infiltrating lymphocyte density on flow cytometry. These results support continued investigation of CRISPR-augmented immunotherapy strategies for GBM.

1. Introduction

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults, accounting for approximately 14.5% of all primary brain tumors and 48.6% of malignant primary brain tumors in the United States (Ostrom et al., 2022). Despite aggressive multimodal therapy consisting of surgical resection, radiotherapy, and temozolomide chemotherapy, the median overall survival for newly diagnosed GBM patients remains approximately 14.6 months, with a five-year survival rate of less than 7% (Stupp et al., 2017).

The immunosuppressive tumor microenvironment in GBM presents a significant barrier to effective immunotherapy. Tumor cells frequently upregulate programmed death-ligand 1 (PD-L1), which engages the PD-1 receptor on tumor-infiltrating lymphocytes (TILs) and suppresses anti-tumor immune responses (Berghoff et al., 2015). Anti-PD-1 immune checkpoint blockade has shown promise in other solid tumors but has demonstrated limited efficacy in GBM, with response rates in clinical trials below 10% (Reardon et al., 2020).

We propose that combining anti-PD-1 immunotherapy with CRISPR-Cas9-mediated knockout of PD-L1 directly on tumor cells could overcome this limitation by simultaneously blocking the PD-1/PD-L1 axis on multiple fronts.

2. Materials and Methods

2.1 Cell Lines and CRISPR Editing

GL261 murine glioblastoma cells were obtained from the National Cancer Institute repository. CRISPR-Cas9 ribonucleoprotein complexes targeting the murine *Cd274* gene (encoding PD-L1) were delivered via electroporation. Knockout efficiency was confirmed by flow cytometry and Sanger sequencing (95.2% editing efficiency at the target locus).

2.2 Mouse Model

Eight-week-old C57BL/6J mice (Jackson Laboratory) were used in all experiments. Animals were maintained under specific pathogen-free conditions according to institutional animal care and use committee protocols. Intracranial implantation of 1×10^5 GL261 cells (WT or PD-L1 KO) was performed stereotactically.

2.3 Treatment Arms

Mice were randomized into four treatment arms (n=24 each): - Control (vehicle only) - Anti-PD-1 monotherapy (200 μg IP, days 7, 10, 13 post-implantation) - CRISPR PD-L1 KO (implanted with edited cells, no anti-PD-1) - Combination (CRISPR PD-L1 KO + anti-PD-1)

2.4 Statistical Analysis

Survival data were analyzed using Kaplan-Meier curves with log-rank tests. Flow cytometry data were compared via one-way ANOVA with Tukey's post-hoc correction. Significance threshold was set at $p < 0.05$.

3. Results

3.1 Combination Therapy Extends Survival

Mice in the combination arm showed a median survival of 38 days, compared to 26 days in the anti-PD-1 monotherapy arm ($p = 0.003$) and 21 days in the control arm ($p < 0.001$). The CRISPR-only arm extended survival modestly to 24 days but did not reach significance against control ($p = 0.067$).

3.2 Increased Tumor-Infiltrating Lymphocytes

Flow cytometric analysis of tumor tissue harvested at day 14 revealed a 2.3-fold increase in CD8+ TILs in the combination arm compared to anti-PD-1 monotherapy ($p = 0.001$). Granzyme B expression among CD8+ TILs was elevated 1.8-fold ($p = 0.008$), suggesting enhanced cytotoxic activity.

3.3 No Significant Adverse Events

No treatment-related deaths or significant weight loss (defined as >15% baseline) were observed in any treatment arm.

4. Discussion

This study demonstrates that CRISPR-mediated PD-L1 knockout synergizes with anti-PD-1 immunotherapy to enhance survival in a syngeneic GBM mouse model. The 47% improvement in median survival represents a clinically meaningful effect size, particularly given the historical resistance of GBM to checkpoint blockade.

The mechanistic basis for synergy likely involves complementary disruption of the PD-1/PD-L1 axis: CRISPR removes PD-L1 from tumor cells directly, while anti-PD-1 blocks any residual PD-1 engagement from tumor-derived or stromal PD-L1. This dual targeting may explain the enhanced T-cell infiltration observed in our combination arm.

4.1 Limitations

Several limitations constrain the generalizability of these findings. First, the GL261 model, while widely used, does not fully recapitulate the heterogeneity of human GBM. Second, CRISPR editing was performed *ex vivo* prior to implantation; *in vivo* delivery of CRISPR components remains a significant translational hurdle. Third, follow-up duration was limited to 60 days post-implantation, precluding analysis of long-term durability.

4.2 Future Directions

Future studies should explore *in vivo* CRISPR delivery via adeno-associated viral vectors or lipid nanoparticles, evaluate combination with additional checkpoint inhibitors (e.g., anti-CTLA-4, anti-TIM-3), and assess efficacy in patient-derived orthotopic xenograft models.

5. Conclusion

Combination CRISPR-Cas9 PD-L1 knockout with anti-PD-1 immunotherapy significantly improves survival in a syngeneic murine GBM model. These preclinical findings support continued investigation of CRISPR-augmented immunotherapy as a therapeutic strategy for glioblastoma.

Acknowledgments

The author thanks Dr. Sarah Chen (Stanford University, Department of Biology) for research supervision and Coach Jo (Gifted Gabber) for mentorship throughout the program. This research was conducted as part of the Gifted Gabber Cancer Research Program.

References

1. Berghoff, A. S., et al. (2015). Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro-Oncology*, 17(8), 1064-1075.

2. Ostrom, Q. T., et al. (2022). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. *Neuro-Oncology*, 24(Supplement_5), v1-v95.

3. Reardon, D. A., et al. (2020). Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. *JAMA Oncology*, 6(7), 1003-1010.

4. Stupp, R., et al. (2017). Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. *JAMA*, 318(23), 2306-2316.